Compare Freeport-McMoRan Inc (FCX) vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Freeport-McMoRan Inc vs Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) — how do they compare? Freeport-McMoRan Inc trades at $73.88 (market cap $102.16B), while Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.71 (market cap $58.74B). The key difference: Freeport-McMoRan Inc is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays the higher dividend (3.33%). Which is the better fit depends on your goals — on Pluang, investors hold Freeport-McMoRan Inc for 69 Days and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days on average.
| FCX | TAK | |
|---|---|---|
Market Cap | $102.16B | $58.74B |
Volume | 9,047,971 | 3,110,994 |
Sector | Basic Materials | Health |
52-Week High | $79.91 | $19.05 |
52-Week Low | $38.65 | $13.23 |
Typical Hold Time | 69 Days | 1 Days |
Enterprise Value | $108.44B | $86.65B |
Dividend Yield | 0.84% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FCX trades at $73.29, up 1.98% on the day, with a bearish technical signal but strong fundamental support. The company has beaten EPS estimates for three consecutive quarters, with Q3 2026 results pending. Revenue is stable at $25.9B (2025), and net income margin improved to 11.38%. Analyst consensus is a Buy (60.97%), with a price target of $73.27. Recent news highlights copper demand growth driven by AI and data centers, positioning FCX to benefit.
FCX offers exposure to rising copper demand, supported by operational efficiency and expansion projects. Risks include cost pressures and regulatory scrutiny. The stock's valuation metrics (P/E 34.87, P/S 3.97) suggest premium pricing, requiring sustained earnings growth to justify upside. Institutional sentiment remains positive, but investors should monitor Q3 earnings and copper price trends.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →
